VEEV

TentativeAI Memo

Veeva

As of 2026-09-09/Confidence high

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-09-09 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Report quality notice

peer set is too generic or lacks enough direct operating comparators

Action

—

Confidence

high

Horizon

—

Key catalyst

Q2 FY2027 results exceeded guidance • 2026-08-26

Base target: $292 / p=50% prob

Biggest risk

The AI/Falcon opportunity is still early, with only five early adopters and initial go-lives still pending. Customer wins are mostly aggregate or anonymous, so the revenue conversion and timing are not yet quantifiable. Recent officer open-market sales are a secondary sentiment headwind, not operating evidence. [#REL-a69f20cc-abce-4c34-8185-b6c46ee86f2f] [#SEC-FORM4-2026-08-31]

Invalidation

Break below $225 or thesis failure.

What would change my mind?

The Q2 print showed durable growth and profitability, with revenue up 18%, subscription revenue up 16%, and management stating that results exceeded guidance while the full-year view improved. Vault CRM adoption and AI product development provide additional multi-year expansion paths. [#SEC-8K-2026-08-26]

Research note

Recommendation

—

Confidence

high

As of

2026-09-09

Base target

$292

p=50%

Bull target

$330

p=25%

Bear target

$225

p=25%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

Vault CRM and cross-cloud adoption expansion
The Q2 print showed durable growth and profitability, with revenue up 18%, subscription revenue up 16%, and management stating that results exceeded guidance while the full-year view improved.
Vault CRM adoption and AI product development provide additional multi-year expansion paths.

BearKey bullets

Adoption counts and customer wins do not disclose contract value, revenue contribution, or customer concentration.
Falcon go-live timing and conversion from early adopters into material recurring revenue remain unproven.
Post-earnings analyst revisions, consensus surprise detail, and verified market-reaction attribution are unavailable.

WatchKey bullets

Q2 FY2027 results exceeded guidance

Summary

High-level snapshot

Recommendation

Model confidence

high

Timeframe

Asset

Equity

Trigger

Base case: $292 (p=50%)

Target spread vs base: +13% / -23%

Scenario probabilities

Bull Target: $330 (p=25%)Base Target: $292 (p=50%)Bear Target: $225 (p=25%)

Commentary

Official Q2 results and management commentary are clearly positive, but the supplied post-print analyst revision set and price-reaction attribution are unavailable. Secondary headlines are mixed and social coverage is absent, so sentiment supports a monitoring-positive view rather than a high-conviction upgrade. [#SEC-8K-2026-08-26]

As of 2026-09-09 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

Vault CRM and cross-cloud adoption expansion

Scenarios

Bull Target (Scenario probability)

$330 / p=25% prob

Base Target (Scenario probability)

$292 / p=50% prob

Bear Target (Scenario probability)

$225 / p=25% prob

Analysis 2026-09-09 · RankAlpha Sentiment Codex

Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

News Sentiment (30d)

0.20

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2026-08-26
Q2 FY2027 results exceeded guidance
Veeva reported Q2 revenue of $928.0 million, up 18% year over year, subscription revenue of $766.8 million, up 16%, and non-GAAP operating income of $415.9 million, up 18%. Management said results exceeded guidance and the full-year view improved across the board. [#SEC-8K-2026-08-26]
Prob 100.00% • Move 0.00% • Priced-in 90.00%
EVENT2026-12-31
Veeva Falcon initial go-lives
Falcon is moving quickly with five early adopters and is on track for initial go-lives during 2026. Execution and conversion from early adoption into material recurring revenue remain unproven. [#SEC-8K-2026-08-26] [#REL-a69f20cc-abce-4c34-8185-b6c46ee86f2f]
Prob 60.00% • Move 7.00% • Priced-in 50.00%

Short-term Catalysts

Next few weeks

No short-term catalysts

Long-term Catalysts

Months to a year

Vault CRM and cross-cloud adoption expansion
2026-12-31
More than 180 Vault CRM customers were live, including five top-20 biopharmas, while a top-20 biopharma deployed Vault CRM and the Agentic Call Report across its full U.S. field team. Development Cloud, Quality Cloud, and Veeva Safety also showed adoption breadth, though customer economics are undisclosed. [#SEC-8K-2026-08-26] [#REL-48e8506a-99d0-43aa-baf1-1fff9a38099d] [#REL-a84aa2b0-27cd-41f2-9c3c-eeac8a2382d0] [#REL-0db95f67-6157-4abe-96f4-6b4fda138e16] [#REL-e1503cb3-d54d-4635-9190-cd3e5f9c9206]
Prob 65% • Move 8% • Priced-in 60%

Risks

Adoption counts and customer wins do not disclose contract value, revenue contribution, or customer concentration.
Falcon go-live timing and conversion from early adopters into material recurring revenue remain unproven.
Post-earnings analyst revisions, consensus surprise detail, and verified market-reaction attribution are unavailable.
Recent officer open-market sales may weigh on sentiment, but Form 4 activity does not establish a change in operating fundamentals. [#SEC-FORM4-2026-08-31]

Peers

Symbol	Summary
ABT	Loose same-sector medtech candidate; hardware and diversified healthcare exposure differ materially from Veeva's life-sciences cloud model, so it is not a direct valuation anchor.
BSX	Loose same-sector medtech candidate with procedure and device exposure; not directly comparable to Veeva's recurring enterprise software economics.
EW	Loose same-sector medtech candidate; useful only for broad healthcare sentiment context, not direct operating or valuation comparison.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-09-09

Loading AI feed…

Symbol

Summary

ABT

Loose same-sector medtech candidate; hardware and diversified healthcare exposure differ materially from Veeva's life-sciences cloud model, so it is not a direct valuation anchor.

BSX

Loose same-sector medtech candidate with procedure and device exposure; not directly comparable to Veeva's recurring enterprise software economics.

Loose same-sector medtech candidate; useful only for broad healthcare sentiment context, not direct operating or valuation comparison.